Opinion

Video

ASRS 2023: Presenters share research from 2023 ASRS annual meeting they find exciting

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, MPH, and Dante Pieramici, MD had to say!

Video Transcript

Editor's note - This transcript has been edited for clarity.

Ursula Schmidt-Erfurth, MD:

What particularly excites everyone are the advances in developing GA therapy. There are multiple therapeutic targets. And there are very many positive signals from different trials using different substances and different approaches. And this is an enormous breakthrough for our patients.

Veena Raiji, MD, MPH:

You know, I think there's a lot of exciting and novel therapeutic interventions for the treatment of intraocular inflammation and uveitis, in particular, novel delivery methods and significant reduction in treatment burden that I think represents the future of ophthalmology, specifically in retina.

Dante Pieramici, MD:

Yeah, I think there's a lot of interesting things going on in our space right now. You know, the, your we're seeing potential treatments for geographic atrophy. But certainly we're also seeing some potential complications that can come from new drugs, things like ocular retinal vasculitis and such. So I think we have to be careful with these new technologies. I'm particularly excited about gene therapy. I think that there's really been proof of concept that this can be used in our patients, particularly our patients with neovascular AMD. And it's really the beginning of the use of gene therapy. So we're seeing models 1.0. And I think that over the years, we'll get better viral vectors, better gene cassettes delivering the material to the eye, and this will be a very relevant approach to treating patients in the next decades to come.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.